Could less be more? new study tests lower drug dose to keep leukemia at bay
NCT ID NCT07163793
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This study looks at whether a lower dose of the drug venetoclax can help people with acute myeloid leukemia (AML) stay in remission while causing fewer serious side effects. About 41 adults whose AML is in remission after initial treatment will take a reduced dose of venetoclax. The main goal is to see if this approach avoids dangerously low white blood cell counts, while still keeping the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA IN REMISSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zuckerberg Cancer Center
RECRUITINGNew Hyde Park, New York, 11042, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.